Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Barinthus Biotherapeutics ( (BRNS) ).
On March 13, 2026, Barinthus Bio reported full-year 2025 results, highlighted by a proposed all-stock merger with diabetes-focused Clywedog Therapeutics, expected to close in the second quarter of 2026 and create a combined Nasdaq-listed entity named Clywedog Therapeutics Holdings, Inc. with an estimated cash runway through 2027. Over 2025, the company executed a strategic refocus on immunology and inflammation, advanced its Phase 1 AVALON trial of VTP-1000 in celiac disease with encouraging single ascending dose safety and pharmacodynamic data, significantly reduced R&D spending to $25.6 million as legacy programs wound down, and ended the year with $71.9 million in cash while preparing for multiple clinical milestones, including Phase 1 multiple ascending dose data for VTP-1000 in the second half of 2026 and four clinical readouts within 18 months of the merger closing.
In January 2025, Barinthus Bio announced a restructuring to prioritize immune tolerance programs such as VTP-1000 and to deprioritize infectious disease and oncology assets, which contributed to lower 2025 R&D outlays versus 2024. During 2025 the company also presented positive Phase 2 data for legacy hepatitis B candidate VTP-300, completed the single ascending dose portion of the AVALON trial in December, and in early 2026 amended its merger agreement with Clywedog to adjust exchange ratio flexibility and minimum cash terms, underscoring management’s focus on preserving financial flexibility and building a differentiated metabolic and autoimmune pipeline for existing and new institutional investors.
The most recent analyst rating on (BRNS) stock is a Sell with a $0.71 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.
Spark’s Take on BRNS Stock
According to Spark, TipRanks’ AI Analyst, BRNS is a Neutral.
The score is driven primarily by weak financial performance (no TTM revenue, large losses, and ongoing cash burn). Technicals add pressure with a below-long-term-average price and negative MACD, while corporate events are mixed—Nasdaq bid-price non-compliance is a major risk despite encouraging early clinical-trial progress.
To see Spark’s full report on BRNS stock, click here.
More about Barinthus Biotherapeutics
Barinthus Biotherapeutics, listed on Nasdaq as BRNS, is an immunology and inflammation specialist developing therapies that promote immune tolerance with curative potential. The company has strategically refocused on autoimmune and metabolic indications, led by its VTP-1000 program in celiac disease, while deprioritizing infectious disease and oncology assets that will now advance only with partners.
Average Trading Volume: 55,362
Technical Sentiment Signal: Sell
Current Market Cap: $24.5M
For an in-depth examination of BRNS stock, go to TipRanks’ Overview page.